# 1 Association between BMI and cause-specific long-term mortality

# 2 in acute myocardial infarction patients.

- 3
- 4 Timo Schmitz<sup>1</sup>, Dennis Freuer<sup>1</sup>, Philip Raake<sup>2</sup>, Jakob Linseisen<sup>1</sup>, Christa Meisinger<sup>1</sup>

### 5

- <sup>6</sup> <sup>1</sup> Epidemiology, Medical Faculty, University of Augsburg, Augsburg, Germany
- <sup>7</sup><sup>2</sup>University Hospital Augsburg, Department of Cardiology, Respiratory Medicine and Intensive Care,
- 8 Augsburg, Germany
- 9
- 10 Corresponding author:
- 11 Dr. Timo Schmitz,
- 12 Epidemiology, Medical Faculty, University of Augsburg, Augsburg, Germany
- 13 Stenglinstraße 2
- 14 86156 Augsburg
- 15 Germany
- 16 Email: timo.schmitz@med.uni-augsburg.de
- 17 Tel.: +49 821-400-4506

18

Background: To investigate the association between body mass index (BMI) at acute

#### 19 Abstract

20

myocardial infarction (AMI) and all-cause as well as cause-specific long-term mortality. 21 Methods: The analysis was based on 10,651 hospitalized AMI patients (age 25-84 years) 22 recorded by the population-based Myocardial Infarction Registry Augsburg between 2000 and 23 24 2017. The median follow-up time was 6.7 years [IQR: 3.5-10.0)]. Cause-specific mortality was obtained by evaluating the death certificates. In multivariable-adjusted COX regression 25 models using cubic splines for the variable BMI, the association between BMI and 26 27 cause-specific mortality (all-cause, cardiovascular, ischemic heart diseases, cancer) was investigated. Additionally, a subgroup analysis in three age groups was performed for 28 all-cause mortality. 29

30 *Results:* Overall, there was a statistically significant U-shaped association between BMI at 31 AMI and long-term mortality with the lowest hazard ratios (HR) found for BMI values between 32 25 and 30 kg/m<sup>2</sup>. For cancer mortality, higher BMI values > 30 kg/m<sup>2</sup> were not associated with 33 higher mortality. In patients aged <60 years, there was a significant association between BMI 34 values > 35 kg/m<sup>2</sup> and increased all-cause mortality; this association was missing in 60 to 84 35 years old patients. For all groups and for each specific cause of mortality, lower BMI (< 36 25kg/m<sup>2</sup>) values were significantly associated with higher mortality.

*Conclusions:* Overall, a lower BMI – and also a high BMI in patients younger than 60 years seem to be a risk factors for increased all-cause mortality after AMI. A BMI in a mid-range
between 25 and 30 kg/m<sup>2</sup> is favorable in terms of long-term survival after AMI.

**Key words:** BMI, acute myocardial infarction, long-term mortality, cause-specific mortality

#### 43 What is Known?

44	•	Obesity is considered a major risk factor for cardiovascular diseases and coronary artery
45		disease.
46	•	Nonetheless, the results of prior studies indicated lower mortality for overweight and obese
47		individuals after acute myocardial infarction (AMI); a phenomenon often called 'obesity
48		paradox'.
49	What	the Study Adds
50	•	This study analyzed the association between body mass index (BMI) and cause-specific
51		long-term mortality after AMI in a population-based cohort of 10.000 AMI patients recorded
52		by the Myocardial Infarction Registry Augsburg.
53	•	The obesity paradox was partially confirmed, as we found a U-shaped association between
54		BMI and long-term mortality with the lowest risk of mortality in overweight individuals.
55	•	For cancer mortality and in elderly, obesity (BMI > $30 \text{ kg/m}^2$ ) was not associated with
56		mortality. Lower BMI < 25 kg/m <sup>2</sup> went along with significantly higher mortality in all age
57		groups and for all causes of death (all-cause, cardiovascular, ischemic heart disease, cancer)

58

59

#### 60 1. Introduction

61 Extreme body mass indices (BMI) are known to be a major risk factor for several diseases. Very low BMI (e.g. in anorexia or cancer cachexia) as well as very high values in obese 62 individuals go along with increased risk of mortality  $1^{-3}$ . Especially obesity is considered to be 63 64 an important risk factor for metabolic diseases like diabetes mellitus and, closely linked to that, a risk factor for several cardiovascular diseases as well  $^{4-6}$ . However, for patients with 65 coronary artery disease (CAD) or acute myocardial infarction, prior studies have reported 66 67 conflicting results regarding the association between high BMI values and long-term 68 mortality: Some researchers found decreased mortality for patients with obesity, often referred to as the 'obesity paradox'  $^{7-14}$ ; a phenomenon that was questioned by the results of 69 several other studies <sup>15,16</sup>. Thus, the true nature of the association between BMI and long-term 70 71 mortality in AMI survivors remains controversial. The present study aims to contribute to a clearer and deeper understanding of this complex relationship. To do so, a large unselected 72 73 sample with high quality data is required, which in this case is derived from the population-based Myocardial Infarction Registry Augsburg. Next to BMI and all-cause 74 75 mortality, there is also a lack of knowledge on the association between BMI and 76 cause-specific mortality, like cardiovascular diseases (CVD) mortality, ischemic heart disease mortality or cancer mortality. Finally, the impact of age on the associations between BMI and 77 mortality will be investigated. 78

79

80 2. Methods

### 81 2.1 Study population

The study used data from the Myocardial Infarction Registry in Augsburg. It was initially established in 1984 as part of the World Health Organization (WHO) project MONICA (Monitoring Trends and Determinants in Cardiovascular Disease). For almost 40 years, all cases of non-fatal AMI and coronary deaths in the study region (city of Augsburg and the two adjacent counties, approximately 680,000 inhabitants) were registered. Inclusion criteria for patients were: primary residence in the study region and age between 25 and 74 years (until 2008) and 25-84 years (from 2009-2017), respectively.

Detailed information on case identification, classification and quality control of the data can be found in a previous publication <sup>17</sup>. All study participants gave written informed consent. Methods of data collection and questionnaires have been approved by the ethics committee of the Bavarian Medical Association (Bayerische Landesärztekammer) and the study was performed in accordance with the Declaration of Helsinki. The study was registered at the German Register of Clinical Studies (DRKS, project number DRKS00029042).

#### 95 2.2 Data collection

96 During their hospital stays, patients were interviewed by trained study nurses using a 97 standardized questionnaire. Additionally, the patients' medical chart was reviewed in detail to 98 confirm the information obtained by the interview and to collect additional data. By this 99 procedure, a wide range of demographic data, data on cardiovascular risk factors, medical 100 history, comorbidities, laboratory values, diagnostics, treatment and medication were 101 collected for each patient.

In particular, information about body weight and height were obtained from the patient's medical file. The variable BMI was calculated as weight in kg divided by the squared height in meters. Renal function according to the estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula.

106 2.3 Outcome

107 The outcome of this study was all-cause and cause-specific long-term mortality. Mortality 108 was ascertained by regularly checking the vital status of all registered AMI patients in cooperation with the regional population registries. Death certificates were obtained from 109 110 local health departments. Additionally, for each deceased patient, a standardized questionnaire 111 was sent out to the former general practitioner and/or coroner. The questionnaire includes, among other topics, questions about preexisting comorbidities and diseases, circumstances of 112 113 the acute event (e.g., reanimation) and specific medication. The main cause of death, encoded by the ICD-10 classification <sup>18,19</sup>, was determined on the base of the death certificate. CVD 114 deaths included all deaths encoded by IOO to I99, ischemic heart diseases were defined as 115 116 deaths encoded by I20 to I25 and finally, cancer deaths included the ICD-10 codes C00 to D48. 117

#### 118 2.4 Statistical analysis

For categorical variables, the results were presented as absolute frequencies with percentages and the Chi-square test was used to test for differences between groups. For normally-distributed continuous variables, the results were presented as means with standard deviations and we used Student's t-tests to test for differences. For non-normally distributed

123 continuous variables the results were presented as medians with inter-quartiles ranges and124 nonparametric tests were applied.

As there was no follow-up information on BMI over time, we limited the post-AMI observational time to 10 years; patients with longer observational times were censored after 10 years. To concentrate on long-term mortality, all patients with an observational time of 28 days and less (the common definition of short-term mortality in the Augsburg Myocardial Infarction Registry is death within 28 days after AMI) were excluded from the analysis.

# 130 2.5 COX regression analyses

Multivariable-adjusted COX proportional hazard regression models were used to analyze the 131 132 association between BMI and all-cause and cause-specific long-term mortality (CVD mortality, ischemic heart disease (IHD) mortality and cancer mortality). The relationship 133 between BMI and mortality was modeled using restricted cubic splines (RCS) with 4 knots (at 134 the 5th, 35th, 65th and 95th percentiles), which allows to capture a potential non-linear 135 association; the reference BMI value was set to 27.5 kg/m<sup>2</sup>. The models were adjusted for the 136 continuous variable age (in years) and the categorical variables sex (male/female), diabetes 137 138 (yes, no), hypertension (yes, no), smoking (current, ex-smoker, never smoker, smoking status unknown), renal function according to eGFR (≥ 60ml/min, 30-59ml/min, < 30ml/min, 139 140 unknown), left-ventricular ejection fraction (EF) ( $\leq 30\%$ , >30%, unknown), type of infarction (STEMI, NSTEMI, other/unknown), percutaneous coronary intervention (PCI) (yes, no) and 141 bypass therapy (yes, no). 142

143	The proportional hazard assumptions were checked graphically by inspecting the Kaplan
144	Meier survival curves as well as log(-log(survival)) plots; for the continuous variables BMI
145	and age the survival curves stratified for the corresponding quartiles were inspected.
146	In a subgroup analysis, we calculated the COX regression models stratified for three age
147	groups: age $< 60$ years between 60 and 74 years, and $\ge 74$ years.
148	Furthermore, we calculated all models not using splines, but quartiles for the variable BMI
149	(displayed in the supplementary material). Finally, we performed two sensitivity analyses:
150	First, we calculated the COX model for the outcome 'cancer mortality' only including cases
151	with a follow-up time of two years and more (also excluding deaths within the first 2 years).
152	Second, we calculated all models only for patients who never smoked cigarettes (also
153	displayed in the supplementary material).

All statistical analyses were carried out with the R program version 4.3.2. A p value of < 0.05</li>
was considered as statistically significant.

156

#### 157 3. Results

Baseline characteristics of the study sample were displayed in table 1. The mean age was 63.7 (11.1) years and 73.3% of all patients were men. During the observational time of up to ten years, 2,770 deaths were recorded among the 10,651 AMI patients. In total, 1,435 (51.8%) deaths were classified as CVD deaths, 1,042 (37.6%) deaths were due to ischemic heart disease and 577 (20.8%) due to cancer. Elderly patients  $\geq$ 75 years were less likely to die because of cancer and had more comorbidities (diabetes, hypertension, impaired renal function) compared

164	to AMI patients $< 75$ years; the percentage of current smokers decreased from 58.0% among
165	patients < 60 years to only 7.0% in the group $\ge$ 75 years. PCI was performed in 70.5% of all
166	cases, with the highest frequency in the age group $< 60$ years and the lowest frequency among
167	the elderly, aged $\geq 75$ years.

#### 168 3.1 All-cause and cause-specific mortality - total sample

169 There was a U-shaped association between BMI and long-term all-cause mortality in the total sample (figure 1A). Compared to the reference BMI value of 27.5 kg/m<sup>2</sup>, patients with a BMI of 170 20 kg/m<sup>2</sup> had a highly increased risk of mortality (HR 2.14 [1.91,2.40]); patients with BMI 171 172 values of 25 and 30 kg/m<sup>2</sup> had HRs of 1.04 [0.99,1.10] and 1.08 [1.03,1.14] respectively. Obese 173 patients again had an increased risk of mortality with HRs of 1.22 [1.12,1.33] and 1.36 [1.15,1.61]. Table S1 displays HR values and 95%CI for specific BMI values and for each 174 175 outcome). The U-shaped relation for all-cause mortality was confirmed by the COX model using BMI quartiles: the first and the fourth quartile had significantly higher HR values 176 compared to the second quartile (reference group) (supplementary table S2). A similar result 177 178 was obtained for CVD mortality (figure 1B). For ischemic heart diseases there appeared to be a 179 U-shaped association as well (figure 1C), but the results were no longer significant for high 180 BMI values. A different constellation was found for cancer mortality: low BMI levels were still 181 strongly associated with higher mortality, but for patients with high BMI values we didn't observe a higher cancer mortality risk (figure 1D). 182

### 183 **3.2** All-cause mortality in different age groups

For the age group < 60 years, there was a pronounced U-shaped association between BMI and</li>
all-cause mortality (figure 2A). Nevertheless, in the regression model using BMI quartiles, only

186	the first, but not the fourth BMI quartile was significantly associated with mortality compared
187	to the second quartile (reference), see table S2. In the age group 60-74 years there was also a
188	U-shaped association (figure 2B) and a significant higher mortality for patients in the first and
189	fourth quartile, see table S2. For the elderly group $\geq$ 75 years however, higher BMI levels were
190	not associated with higher mortality (figure 2C and table S2). Hence, low BMI levels were
191	significantly associated with an elevated risk of dying for all age groups, (figure 2), but only for
192	AMI patients < 75 years high BMI values were also significantly associated with increased
193	mortality.
194	3.3 Sensitivity analyses
195	Excluding all cases with an observational time of less than two years had only minor impact on
196	the association between BMI and cancer mortality, see table S2 and figure S1 (supplementary
197	material). Moreover, including only never smokers into the COX models had moderate effect
198	on the results: While the general shape of the associations between BMI and all-cause and
199	cause-specific mortality was confirmed (in particular lowest mortality for BMI between 25 and
200	$30 \text{ kg/m}^2$ ), the strengths of the associations appeared to be moderately attenuated (in terms of
201	lower HR values compared to the main models), see figures S2 and S2, supplementary material.

#### 203 4. Discussion

In this study, we found an overall U-shaped association between BMI and long-term mortality
after AMI. For the older age group (>75 years) as well as for cancer mortality, however, high
BMI values were not associated with higher risk for early mortality.

### 207 High BMI values and long-term mortality

Several prior studies have examined the relationship between (high) BMI and long-term 208 mortality after myocardial infarction, and thereby reporting conflicting results. Some studies 209 210 and meta-analyses indicated a survival benefit for patients with higher BMI in CAD, acute coronary syndrome and AMI <sup>7-14</sup>; a phenomenon often referred to as the 'obesity paradox'. 211 This phenomenon is only partially confirmed by the present study, as we found the lowest 212 mortality for patients with BMI values between 25 and 30 kg/m<sup>2</sup>, which is categorized as 213 'pre-obesity' or 'overweight' by the WHO classification  $^{20}$ . For BMI > 30 kg/m<sup>2</sup>, which is 214 classified as obesity, mortality began to increase. These observations are supported by a 215 recent study from Sweden analyzing over 25,000 STEMI patients; they found the lowest 216 1-year all-cause mortality for the overweight group (BMI 25.0–29.9 kg/m<sup>2</sup>)  $^{21}$ . 217

In fact, there are prior studies and meta-analyses that question this 'obesity paradox' in CAD and AMI patients <sup>15,16</sup>. One example is a recent study by Al-Shaar et al. <sup>16</sup>; they found higher mortality for patients with higher BMI for all-cause and CVD mortality, which is in line with our results.

The 'obesity paradox' would somehow contradict the concept of overweight and obesity being a strong risk factor for the development of cardiovascular diseases. Our results actually suggest that obesity with  $BMI > 30 \text{ kg/m}^2$  is also a risk factor for increased mortality in AMI patients and in this sense consistent with the concept of obesity being a cardiovascular risk factor not only in primary (and secondary), but also in tertiary prevention.

227 Low BMI values and long-term mortality

12

In prior publications it has been reported, that lower BMI  $< 25 \text{ kg/m}^2$  is associated with 228 increased long-term mortality in CAD and AMI 7,8,11,12,21,22, which is well in line with the 229 results of the present study. However, there are studies reporting contradicting results <sup>16</sup>. In 230 the above mentioned study by Al-Shaar et al. for instance, lower BMI values were only 231 non-significantly associated with slightly increased mortality <sup>16</sup>. They speculated, that this 232 might be an artifact caused by unintentional weight loss due to preexisting disease (reverse 233 causation). Especially, patients with preexisting cancer might drive this potential reverse 234 causation, which also might be applicable to the present study. However, our results were very 235 clear in this respect: we observed a higher mortality for lower BMI not only for all-cause and 236 cancer mortality, but also for CVD mortality and IHD mortality. Moreover, we performed a 237 sensitivity analysis for cancer mortality by excluding all patients with an observational time 238 of less than 2 years, thus excluding patients with preexisting, severe and advanced underlying 239 diseases such as cancer. But still, BMI values  $< 25 \text{ kg/m}^2$  were strongly associated with 240 higher mortality. Therefore, the here reported associations between lower BMI and higher 241 mortality are regarded as valid and important findings. 242

### 243 All-cause mortality and age groups

While there was a pronounced U-shaped association between BMI and all-cause mortality for AMI patients younger than 60 years, there was no association between higher BMI values and mortality in the elderly group. We can only speculate about the reason for this observation: Younger AMI patients have a higher life expectancy after their infarction compared to older patients. Prior studies reported that a longer duration of obesity is associated with increased risk of developing secondary diseases like diabetes mellitus <sup>23,24</sup> or CDV <sup>25</sup>. So, obesity might

reveal more distinct impacts on health in younger patients, who live long enough to develop 250 251 secondary conditions and are more likely to be affected by life-threatening complications. Older patients in their seventies and eighties on the other hand often struggle to keep their 252 weight: Many are especially affected by sarcopenia, which impacts on bodily functions, 253 including the immune response to infections <sup>26</sup>. Thus, at older age, a higher BMI likely 254 represent higher muscle mass and bigger energy reserves and consequently less frailty. This 255 circumstance might annihilate the effect of obesity-related complications like diabetes and 256 CVD and consequently leading to comparable mortality for obese AMI patients compared to 257 individuals with BMI  $< 30 \text{ kg/m}^2$ . 258

# 259 Mortality and smoking

Many prior studies indicated effects of residual confounding by smoking and/or an interaction 260 between BMI and smoking in mortality analyses <sup>3,16,27–29</sup>. This appears to be not much of a 261 surprise as smoking suppresses appetite which consequently can result in a relevant weight 262 reduction <sup>30</sup>. At the same time, smoking causes premature mortality since cigarette smoke 263 contains a variety of carcinogenic compounds <sup>31</sup> and is involved in the pathophysiology of 264 arteriosclerosis <sup>32,33</sup>. To reflect this circumstance, we adjusted all models for the smoking 265 status of the patients. Moreover, we performed a sensitivity analyses only including patients 266 267 who never smoked cigarettes. This had moderate impact on the associations observed, and the overall shape of the associations was quite similar. Although smoking might be an important 268 factor or confounder regarding the association between BMI and long-term mortality, the 269 results found in this study appear to be applicable mainly independent of the smoking status 270 (even though the effect sizes (HR's) were attenuated). 271

#### 272 Strengths and Limitations

The present study uses data from the population-based Myocardial Infarction Registry Augsburg with complete enrollment, which minimizes selection bias and ensure highest data quality. The number of included AMI cases is high and the follow up of patients is long with a median observational time of 6.7 years. The broad variety of information on comorbidities, treatment etc. enabled the calculation of most complete multivariable-adjusted COX regression models. A particular strength of this study is information on the main cause of death and separate analyses for specific types of mortality.

Nevertheless, there are also some limitations to mention. First, information on BMI was only 280 available for the time of infarction, and there was no follow-up information on BMI. BMI 281 might have changed considerable over the course of up to ten years. Indeed, body-weight 282 fluctuations are quite common <sup>34</sup> and go along with increased mortality in CAD and AMI 283 patients <sup>34,35</sup>. Additionally, measures of body composition, like 'percentage of body fat' or 284 'body fat distribution' might provide important additional information for the analysis of 285 obesity/body composition and mortality <sup>36,37</sup>. Furthermore, over the course of 17 years, which 286 is the time frame for patient recruitment for this analysis, diagnostics, acute treatment and 287 288 prevention of coronary artery diseases and AMI has changed significantly (PCI treatment, 289 troponin diagnostics, medication, etc.), which may have affected the observed associations as well. Our findings may not be generalized to all ethnic groups since no information on 290 ethnicity was available. Finally, we may have not considered all important confounders and 291 292 we cannot exclude reverse causation.

#### 293 5. Conclusion

294	There is a general U-shaped association between BMI and all-cause mortality in AMI
295	patients. This association was most dominant in AMI patients < 60 years; in the elderly group
296	high BMI was not associated with increased mortality. For cancer mortality, only BMI values
297	$<$ 25 kg/m $^2$ were associated with increased mortality; individuals with obesity (BMI $>$
298	$30 \text{kg/m}^2$ ) on the other hand were not more likely to die from cancer. We conclude that
299	patients with a mid-range BMI between 25 and 30 $kg/m^2$ have the most favorable outcome
300	after AMI; especially very low BMI values $< 22 \text{ kg/m}^2$ are associated with higher mortality.

301

# Acknowledgements:

We would like to thank all members of the Helmholtz Zentrum München, Institute of Epidemiology, and the Chair of Epidemiology at the University Hospital of Augsburg, who were involved in the planning and conduct of the study. Steering partners of the MI Registry, Augsburg, include the Chair of Epidemiology at the University Hospital of Augsburg and the Department of Internal Medicine I, Cardiology, University Hospital of Augsburg. Many thanks for their support go to the local health departments, the office-based physicians and the clinicians of the hospitals within the study area. Finally, we express our appreciation to all study participants.

*Sources of Funding:* This work was supported by the Helmholtz Zentrum München, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria and the German Federal Ministry of Health. This research also received support from the Faculty of Medicine, University of Augsburg, and the University Hospital of Augsburg, Germany. Since the year 2000, the collection of MI data has been co-financed by the German Federal Ministry of Health to provide population-based MI morbidity data for the official German Health Report (see <http://www.gbe-bund.de> www.gbe-bund.de).

Conflict of interest: none declared

*Authors' contribution:* TS and CM conceived the study. TS performed the statistical analysis and drafted the manuscript. CM was responsible for the acquisition of the data and supervised the analysis. DF, PR and JL contributed to data acquisition and revised the manuscript. All authors approved the final manuscript.

*Availability of data and materials:* The datasets generated during and/or analysed during the current study are not publicly available due to data protection aspects but are available in an anonymized form from the corresponding author on reasonable request.

*Ethics approval and consent to participate:* Data collection of the MONICA/KORA MI registry has been approved by the ethics committee of the Bavarian Medical Association (Bayerische Landesärztekammer) and the study was performed in accordance with the Declaration of Helsinki. All study participants have given written informed consent.

# References

- Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. *Lancet Diabetes Endocrinol.* 2018;6:944–953. doi: 10.1016/S2213-8587(18)30288-2
- Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309:71–82. doi: 10.1001/jama.2012.113905
- 3. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee I-M, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med*. 2010;363:2211–2219. doi: 10.1056/NEJMoa1000367
- Kachur S, Lavie CJ, Schutter A de, Milani RV, Ventura HO. Obesity and cardiovascular diseases. *Minerva Med.* 2017;108:212–228. doi: 10.23736/S0026-4806.17.05022-4
- Tian X, Chen S, Wang P, Xu Q, Zhang Y, Luo Y, Wu S, Wang A. Insulin resistance mediates obesity-related risk of cardiovascular disease: a prospective cohort study. *Cardiovasc Diabetol*. 2022;21:289. doi: 10.1186/s12933-022-01729-9
- Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. *Front Endocrinol (Lausanne)*. 2023;14:1161521. doi: 10.3389/fendo.2023.1161521
- Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW, Mauri L. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. *Heart*. 2015;101:1631–1638. doi: 10.1136/heartjnl-2014-307119
- Niedziela J, Hudzik B, Niedziela N, Gąsior M, Gierlotka M, Wasilewski J, Myrda K, Lekston A, Poloński L, Rozentryt P. The obesity paradox in acute coronary syndrome: a meta-analysis. *Eur J Epidemiol*. 2014;29:801–812. doi: 10.1007/s10654-014-9961-9
- Angerås O, Albertsson P, Karason K, Råmunddal T, Matejka G, James S, Lagerqvist B, Rosengren A, Omerovic E. Evidence for obesity paradox in patients with acute coronary syndromes: a report

from the Swedish Coronary Angiography and Angioplasty Registry. *Eur Heart J.* 2013;34:345–353. doi: 10.1093/eurheartj/ehs217

- Bucholz EM, Beckman AL, Krumholz HA, Krumholz HM. Excess weight and life expectancy after acute myocardial infarction: The obesity paradox reexamined. *Am Heart J.* 2016;172:173– 181. doi: 10.1016/j.ahj.2015.10.024
- Paola L de, Mehta A, Pana TA, Carter B, Soiza RL, Kafri MW, Potter JF, Mamas MA, Myint PK. Body Mass Index and Mortality, Recurrence and Readmission after Myocardial Infarction: Systematic Review and Meta-Analysis. *J Clin Med.* 2022;11. doi: 10.3390/jcm11092581
- Kanic V, Vollrath M, Frank B, Kanic Z. An obesity paradox in patients with myocardial infarction undergoing percutaneous intervention. *Nutr Metab Cardiovasc Dis*. 2021;31:127–136. doi: 10.1016/j.numecd.2020.08.024
- Liu S-H, Lin Y-Z, Han S, Jin Y-Z. The obesity paradox in ST-segment elevation myocardial infarction patients: A meta-analysis. *Ann Noninvasive Electrocardiol*. 2023;28:e13022. doi: 10.1111/anec.13022
- Wang L, Liu W, He X, Chen Y, Lu J, Liu K, Cao K, Yin P. Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. *Int J Obes (Lond)*. 2016;40:220–228. doi: 10.1038/ijo.2015.176
- 15. Chrysant SG, Chrysant GS. New insights into the true nature of the obesity paradox and the lower cardiovascular risk. *J Am Soc Hypertens*. 2013;7:85–94. doi: 10.1016/j.jash.2012.11.008
- Al-Shaar L, Li Y, Rimm EB, Manson JE, Rosner B, Hu FB, Stampfer MJ, Willett WC. Body Mass Index and Mortality Among Adults With Incident Myocardial Infarction. *Am J Epidemiol*. 2021;190:2019–2028. doi: 10.1093/aje/kwab126
- Löwel H, Meisinger C, Heier M, Hörmann A. The population-based acute myocardial infarction (AMI) registry of the MONICA/KORA study region of Augsburg. *Gesundheitswesen*. 2005;67 Suppl 1:S31-7. doi: 10.1055/s-2005-858241
- WHO. ICD-10 Version:2019 (WHO). https://icd.who.int/browse10/2019/en. Accessed January 12, 2024
- World Health Organization. International statistical classification of diseases and International statistical classification of diseases and related health problems - 10th revision. Fifth edition 2016.

https://iris.who.int/bitstream/handle/10665/246208/9789241549165-V1-eng.pdf. Accessed January 12, 2024

- WHO Europe. A healthy lifestyle WHO recommendations. https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendati ons. Accessed January 12, 2024
- Jamaly S, Redfors B, Omerovic E, Carlsson L, Karason K. Prognostic significance of BMI after PCI treatment in ST-elevation myocardial infarction: a cohort study from the Swedish Coronary Angiography and Angioplasty Registry. *Open Heart*. 2021;8. doi: 10.1136/openhrt-2020-001479
- 22. Yokoyama H, Tomita H, Honda S, Nishihira K, Kojima S, Takegami M, Asaumi Y, Yamashita J, Saji M, Kosuge M, Takahashi J, Sakata Y, Takayama M, Sumiyoshi T, Ogawa H, Kimura K, Yasuda S. Effect of Low Body Mass Index on the Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR). *Circ J.* 2022;86:632–639. doi: 10.1253/circj.CJ-21-0705
- 23. Abdullah A, Stoelwinder J, Shortreed S, Wolfe R, Stevenson C, Walls H, Courten M de, Peeters A. The duration of obesity and the risk of type 2 diabetes. *Public Health Nutr*. 2011;14:119–126. doi: 10.1017/S1368980010001813
- The NS, Richardson AS, Gordon-Larsen P. Timing and duration of obesity in relation to diabetes: findings from an ethnically diverse, nationally representative sample. *Diabetes Care*. 2013;36:865–872. doi: 10.2337/dc12-0536
- Amani-Beni R, Darouei B, Zefreh H, Sheikhbahaei E, Sadeghi M. Effect of Obesity Duration and BMI Trajectories on Cardiovascular Disease: A Narrative Review. *Cardiol Ther*. 2023;12:307– 326. doi: 10.1007/s40119-023-00317-6
- Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. *EBioMedicine*. 2019;49:381–388. doi: 10.1016/j.ebiom.2019.10.034
- Freedman DM, Sigurdson AJ, Rajaraman P, Doody MM, Linet MS, Ron E. The mortality risk of smoking and obesity combined. *Am J Prev Med*. 2006;31:355–362. doi: 10.1016/j.amepre.2006.07.022
- 28. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort

studies with 3.74 million deaths among 30.3 million participants. *BMJ*. 2016;353:i2156. doi: 10.1136/bmj.i2156

- Global BMC, Di Angelantonio E, Bhupathiraju S, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns B, Huxley R, Jackson C, Joshy G, Lewington S, Manson J, Murphy N, Patel A, Samet J, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan J, Smith G, Fang X, Franco O, Green J, Halsey J, Hildebrand J, Jung K, Korda R, McLerran D, Moore S, O'Keeffe L, Paige E, Ramond A, Reeves G, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun Y, Willeit P, Banks E, Beral V, Chen Z, Gapstur S, Gunter M, Hartge P, Jee S, Lam T-H, Peto R, Potter J, Willett W, Thompson S, Danesh J, Hu F. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet*. 2016;388:776–786. doi: 10.1016/S0140-6736(16)30175-1
- Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. *Clin Pharmacol Ther*. 2011;90:164–168. doi: 10.1038/clpt.2011.105
- Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. *Langenbecks Arch Surg*.
   2006;391:603–613. doi: 10.1007/s00423-006-0111-z
- Siasos G, Tsigkou V, Kokkou E, Oikonomou E, Vavuranakis M, Vlachopoulos C, Verveniotis A, Limperi M, Genimata V, Papavassiliou AG, Stefanadis C, Tousoulis D. Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. *Curr Med Chem*. 2014;21:3936–3948. doi: 10.2174/092986732134141015161539
- Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler Thromb Vasc Biol*. 2014;34:509–515. doi: 10.1161/ATVBAHA.113.300156
- Lopez-Jimenez F, Wu CO, Tian X, O'Connor C, Rich MW, Burg MM, Sheps D, Raczynski J, Somers VK, Jaffe AS. Weight change after myocardial infarction--the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) experience. *Am Heart J*. 2008;155:478–484. doi: 10.1016/j.ahj.2007.10.026
- Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. *N Engl J Med*. 2017;376:1332–1340. doi: 10.1056/NEJMoa1606148

- 36. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body Size and Fat Distribution as Predictors of Coronary Heart Disease among Middle-aged and Older US Men. *Am J Epidemiol.* 1995;141:1117–1127. doi: 10.1093/oxfordjournals.aje.a117385
- 37. Schutter A de, Lavie CJ, Patel DA, Artham SM, Milani RV. Relation of body fat categories by Gallagher classification and by continuous variables to mortality in patients with coronary heart disease. *Am J Cardiol.* 2013;111:657–660. doi: 10.1016/j.amjcard.2012.11.013

*Figure 1:* Association between BMI and all-cause and cause specific mortality in the total sample. The COX regression models were adjusted for age, sex, diabetes, hypertension, smoking status, eGFR, left-ventricular EF, type of infarction, PCI and bypass therapy.

*Figure 2:* Association between BMI and all-cause mortality in different age groups. The COX regression models were adjusted for age, sex, diabetes, hypertension, smoking status, eGFR, left-ventricular EF, type of infarction, PCI and bypass therapy.

Table 1: Baseline characteristics of patients with and without diabetes. Categorical data presented as total numbers (%). Numeric data is presented as mean

(SD) or median (IQR).

	Total sample	Age groups			
	(n=10651)	< 60 years	60-74 years	≥75 years	p-value
	. ,	(n = 3604)	(n = 5369)	(n = 1678)	
Sex (male)	7809 (73.3)	2961 (82.2)	3846 (71.6)	1002 (59.7)	<0.001
Age (mean, sd)	63.7 (11.1)	50.9 (6.2)	67.5 (4.3)	78.9 (2.8)	<0.001
BMI in kg/m <sup>2</sup> (median, IQR)	27.1 (24.5-30.1)	27.5 (24.9 - 30.5)	27.1 (24.5 - 30.1)	26.3 (24.0 - 29.3)	<0.001
Mortality					
Total number of deaths*	2770 (26.0)	376 (10.4)	1627 (30.3)	767 (45.7)	<0.001
(% of all cases)					
CVD deaths*	1435 (51.8)	196 (52.1)	829 (51.0)	410 (53.5)	0.515
(% of all deaths)					
Ischemic heart disease deaths*	1042 (37.6)	155 (41.2)	619 (38.0)	268 (34.9)	0.103
(% of all deaths)					
Cancer deaths*	591 (21.3)	106 (28.2)	369 (22.7)	116 (15.1)	<0.001
(% of all deaths)					
Comorbidities and clinical character	eristics				
Diabetes mellitus	3367 (31.6)	809 (22.4)	1893 (35.3)	665 (39.6)	<0.001
Hypertension	8309 (78.0)	2384 (66.1)	4417 (82.3)	1508 (89.9)	<0.001
Smoking status					<0.001
Current smoker	3400 (31.9)	2090 (58.0)	1193 (22.2)	117 (7.0)	
Ex-smoker	3370 (31.6)	815 (22.6)	1953 (36.4)	602 (35.9)	
Never smoker	3265 (30.7)	606 (16.8)	1836 (34.2)	823 (49.0)	
Smoking status unknown	616 ( 5.8)	93 ( 2.6)	387 (7.2)	136 ( 8.1)	

Type of infarction <0.001					
- STEMI	3849 (36.1)	1620 (45.0)	1802 (33.6)	427 (25.4)	
- NSTEMI	5637 (52.9)	1767 (49.0)	2958 (55.1)	912 (54.4)	
- other/unknown	1165 (10.9)	217 ( 6.0)	609 (11.3)	339 (20.2)	
Renal function <0.0					
- GFR >= 60ml/min	5530 (51.9)	2271 (63.0)	2542 (47.3)	717 (42.7)	
- GFR 30-59ml/min	1930 (18.1)	186 ( 5.2)	987 (18.4)	757 (45.1)	
- GFR < 30ml/min	395 ( 3.7)	38 ( 1.1)	183 ( 3.4)	174 (10.4)	
- GFR unknown	2796 (26.3)	1109 (30.8)	1657 (30.9)	30 ( 1.8)	
Therapy					
PCI	7505 (70.5)	2860 (79.4)	3545 (66.0)	1100 (65.6)	<0.001
Bypass therapy	1599 (15.0)	401 (11.1)	963 (17.9)	235 (14.0)	<0.001

\* All deaths occurring in the time period between 28 days until 10 years after AMI







